# GLP-1 receptor agonists: Overview

Source page: https://www.materialinsights.org/technologies/glp1_agonists/tech-overview/

#### What it does

The job the technology does for people, in a short paragraph

GLP-1 receptor agonists are medicines that copy a gut hormone released after meals. They help the body control blood sugar and make people feel full sooner. The first, exenatide, was approved in the United States in 2005 ^[2]. They are used for type 2 diabetes and obesity, conditions that affect 830 million and more than a billion people ^[3, 4].

as of 2026-11-11

#### How it works

The working principle in plain words, step by step

After a meal, cells in the gut release a short protein hormone, GLP-1. It docks on a receptor, a protein on the surface of other cells, like a key in a lock. In the pancreas this tells beta cells to release more insulin when blood sugar is high ^[1]. It also slows the emptying of the stomach and acts on the brain to reduce appetite ^[1]. The natural hormone is broken down within minutes, so it cannot work as a medicine ^[1]. The drugs are peptides changed so that they fit the same receptor but last far longer: exendin-4 from lizard venom, then human GLP-1 with small changes that let it bind to blood proteins and resist breakdown. Semaglutide lasts about 165 hours in the body ^[1].

as of 2026-11-11

#### Key figures

The handful of numbers that size it up, each with its unit, year and source

| Figure | Value | Unit | Year | Source |
|---|---|---|---|---|
| People living with obesity, more than | 1 | billion people | – | ^[3] |
| People living with diabetes | 830 | million people | 2022 | ^[4] |
| Half-life of semaglutide in the body | 165 | hours | – | ^[1] |
| Novo Nordisk's reported sales of Wegovy | 79.1 | billion DKK | 2025 | ^[5] |
| Novo Nordisk's own figure for its share of the world GLP-1 diabetes market by value (IQVIA data, 12 months to November 2025) | 45.8 | % | 2025 | ^[5] |

as of 2026-11-11. The obesity figure is from WHO's guideline of December 2025, which gives no year for it [3]; the sales and market share are Novo Nordisk's own figures from its 2025 financial report, the share based on IQVIA data for November 2025 and covering GLP-1 diabetes medicines only [5].

#### Where it is used

The main places and products the technology is found in

- Type 2 diabetes, to help control blood sugar ^[1]
- Long-term treatment of obesity in adults ^[3]
- Lowering the risk of heart attack and stroke in some people with heart disease and excess weight ^[1]
- Primary care clinics, diabetes and obesity services, and pharmacies

as of 2026-11-11

#### Scale today

How much of it there is now: units in use, made each year and who uses it

**Users**
: Novo Nordisk reports that its diabetes and obesity medicines reached 45.6 million patients in 2025 ^[5]

**Unit**
: people

**Year**
: 2025

**Note**
: The company's own estimate, a 12-month total covering all its diabetes and obesity products, including insulin, so it is only a guide; no world count of GLP-1 users was found.

as of 2026-11-11

#### Sources

1. [GLP-1-based therapy for obesity](https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/) Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
2. [Dr. John Eng to Receive Golden Goose Award](https://www.sciencecoalition.org/2013/07/30/dr-john-eng-to-receive-golden-goose-award/) The Science Coalition, 2013
3. [WHO issues global guideline on the use of GLP-1 medicines in treating obesity](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity) World Health Organization, 2025
4. [Diabetes (fact sheet)](https://www.who.int/News-Room/Fact-Sheets/Detail/Diabetes) World Health Organization, 2026
5. [Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026, Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm) Novo Nordisk A/S, filed with the US Securities and Exchange Commission, 2026

## Other sections

- [Summary](https://www.materialinsights.org/technologies/glp1_agonists/index.md)
- [Science](https://www.materialinsights.org/technologies/glp1_agonists/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/glp1_agonists/tech-evolution/index.md)
- [Materials](https://www.materialinsights.org/technologies/glp1_agonists/tech-materials/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/glp1_agonists/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/glp1_agonists/tech-industries/index.md)
